FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
Press release content from Business Wire. The AP news staff was not involved in its creation. FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease January 21, 2021 GMT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 21, 2021-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and gran...
Source: apnews.com